Will Axovant Catch Lightning in a Bottle With Its Alzheimer's Drug?

Will Axovant Catch Lightning in a Bottle With Its Alzheimer's Drug?

Drug candidates for treating Alzheimer's disease have a 99% failure rate in trials. But Lawrence Friedhoff, who led the team responsible for developing Aricept, is working on a new drug that will increase its efficacy.

In this clip from Industry Focus: Healthcare, Motley Fool analyst Kristine Harjes is joined by contributor Todd Campbell to explain how far along Intepirdine is in its trials, how likely it is to be approved, what a blockbuster drug this could be, and why investors need to still be very cautious about buying into Axovant (NYSE: AXON) today.

A full transcript follows the video.

Continue reading

Source: Fool.com